Compare Sanofi SA (SNY) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Sanofi SA trades at $40.12 (market cap $95.18B), while iShares Broad USD Investment Grade Corporate Bond trades at $48.78 (market cap $17.53B). The key difference: Sanofi SA is far larger — about 5.4× iShares Broad USD Investment Grade Corporate Bond's market cap, and Sanofi SA pays a 6.01% dividend while iShares Broad USD Investment Grade Corporate Bond pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and iShares Broad USD Investment Grade Corporate Bond for 44 Days on average.
| SNY | USIG | |
|---|---|---|
Market Cap | $95.18B | $17.53B |
Volume | 2,995,646 | 4,695,583 |
Sector | Health | Fixed Income |
52-Week High | $52.34 | $52.69 |
52-Week Low | $39.51 | $48.54 |
Typical Hold Time | 94 Days | 44 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
USIG trades at $48.73 with minimal daily movement (+0.1%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators are neutral. Recent institutional activity includes Blue Edge Capital's new $21.9 million position and Bank of New York Mellon increasing its stake. The company maintains regular dividend distributions, with recent payments of $0.20-$0.21 per share.
The outlook remains cautious given bearish technical signals and limited fundamental data availability. Investment opportunity exists through dividend income and institutional confidence, but risks include market volatility and the need for clearer financial performance metrics to assess valuation properly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
